Point/Counterpoint: Dordaviprone for diffuse midline glioma - A landmark approval or a premature step?

Khasraw M, Dun MD, Arrillaga-Romany I, Verhaak RGW, Bouffet E, Hansford JR, Singh K, Mueller S, Koschmann C, Wen PY